Drug prices row: EU health chief hits back at Trump view that Europe is ‘free-loading’ on US innovation

Vytenis Andriukaitis calls ‘fake news’ on Trump drug price blame game. Tariffs on medicines – if ever proposed by the US – would be ‘a humanitarian tragedy’, he says

by Éanna Kelly, Science Business

Health commissioner Vytenis Andriukaitis has flatly rejected the accusation by Donald Trump that “freeloading” Europe is benefiting from US pharmaceutical research. “Sorry to say, it’s fake news; it’s absolutely fake news,” he told Science|Business.

Trump blames high drug prices in the US in part on foreign countries that gain from significant US investment in medical research without paying their fair share of the costs. The White House Council of Economic Advisers issued a report in February that described “free-riding” by wealthy countries as “the root of the problem.”

Continue reading

Advertisements
Posted in Drug prices, Uncategorized | Leave a comment

GSK takes on Gilead in fight for dominance in HIV drugs

Businesslive | 21 June 2018

by Agency Staff

London – GlaxoSmithKline (GSK) is taking its fight with Gilead Sciences for dominance of the HIV market to the world’s leading AIDS conference in July by showcasing detailed results from its new two-drug treatment.

The drug makers are touting rival strategies for fighting the AIDS virus, with GSK betting that a shift to using two drugs rather than the standard three will boost its market share, while Gilead sticks with the tried and tested triple approach. Continue reading

Posted in Uncategorized | Leave a comment

Document exclusivity weakens Norwegian pandemic preparedness

Source: Dagens Medisin | June 20, 2018

IMAGINE THAT A large global o, break of contagious disease also includes Norway, such as a new flu-like disease with high risk of transmission and mortality. Imagine that there is only one effective drug, which is patented, and that the manufacturer demands an unacceptably high price, or that the manufacturer is unable to supply enough on the Norwegian market. Continue reading

Posted in Compulsory Licensing, Patent, Patents | Leave a comment

How the Government Can Lower Drug Prices

Source: The New York Times | June 20, 2018

In Baltimore, the health commissioner, Dr. Leana Wen, uses a need-based algorithm to decide which emergency rooms, needle-exchange vans, E.M.T.s and opioid outreach workers receive the city’s limited supply of naloxone — and which don’t. The drug, which reverses overdoses, has saved some 14,000 Baltimore residents since 2015. But its price has increased in recent years, by between 95 and 500 percent, depending on which version of the medication is being considered. Even with donationsand discounts from drug makers, Dr. Wen says the city can’t afford all the naloxone it needs. Continue reading

Posted in Bad Pharma, Drug prices | Leave a comment

MSF challenges Gilead’s unmerited patent in China for lifesaving hepatitis C medicine, Affordable generic versions from China could save millions of people’s lives

Source: Medecins Sans Frontieres |June 19, 2018

The international medical humanitarian organisation Médecins Sans Frontières (MSF) today filed a legal patent challenge at China’s State Intellectual Property Office (SIPO), requesting the invalidation of the patent granted to US pharmaceutical corporation Gilead Sciences for the oral hepatitis C medicine velpatasvir. The patent is being contested on the grounds that it involves well-known technologies, rendering it an unmerited patent under China’s patent law, which is consistent with the World Trade Organization rules. Continue reading

Posted in Hepatitis C, Patent, Patent Enforcement | Leave a comment

Draft TB declaration: US, EU push against funding, delinkage pledges

Source: POLITICO PRO| June 12, 2018

The EU and U.S. are resisting concrete commitments on new funding for tuberculosis ahead of a high-level U.N. meeting about fighting the world’s top infectious killer.

The two regions are also pushing to eliminate language that would urge countries to work to separate the cost of R&D from the price of a drug — so called delinkage — according to a draft of the political declaration to be signed by heads of state at the U.N. General Assembly on September 26. Continue reading

Posted in Delinkage, Tuberculosis (TB) | Leave a comment

Why pharmaceuticals could be the prescription for trade warfare that truly hurts America

Source: Maclean’s | June 12, 2018

What began as a trade skirmish over Donald Trump’s imposition of a 10-per-cent tariff on Canadian steel and aluminum is now clearly a trade war. The miasma is only just lifting from the G7 summit in Charlevoix, Que., in which a Justin Trudeau press conference over a spiked communiqué sparked a Trump tantrum. Continue reading

Posted in Canada, US Trade tools | Leave a comment